Five-Drug Anti-HIV Treatment Followed by Treatment Interruption in Patients Who Have Recently Been Infected With HIV

PHASE2CompletedINTERVENTIONAL
Enrollment

121

Participants

Timeline

Start Date

May 31, 1999

Study Completion Date

October 31, 2006

Conditions
HIV Infections
Interventions
DRUG

Ritonavir

DRUG

Abacavir sulfate

DRUG

Amprenavir

DRUG

Lamivudine

DRUG

Stavudine

Trial Locations (18)

10003

Beth Israel Med. Ctr. ACTU, New York

10016

NY Univ. HIV/AIDS CRS, New York

10032

Columbia P&S CRS, New York

14607

AIDS Care CRS, Rochester

14642

McCree McCuller Wellness Ctr. at the Connection, Infectious Disease Unit, Rochester

Univ. of Rochester ACTG CRS, Rochester

19104

Hosp. of the Univ. of Pennsylvania CRS, Philadelphia

27514

Unc Aids Crs, Chapel Hill

63110

Washington U CRS, St Louis

80045

University of Colorado Hospital CRS, Aurora

90033

USC CRS, Los Angeles

90035

UCLA CARE Center CRS, Los Angeles

92103

Ucsd, Avrc Crs, San Diego

94110

Ucsf Aids Crs, San Francisco

96816

Univ. of Hawaii at Manoa, Leahi Hosp., Honolulu

02114

Massachusetts General Hospital ACTG CRS, Boston

02720

SSTAR, Family Healthcare Ctr., Fall River

02906

The Miriam Hosp. ACTG CRS, Providence

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00000940 - Five-Drug Anti-HIV Treatment Followed by Treatment Interruption in Patients Who Have Recently Been Infected With HIV | Biotech Hunter | Biotech Hunter